4CPS-184 Comparison of safety and adherence of new oral therapies for the treatment of relapsing-remitting multiple sclerosis

BACKGROUND: Teriflunomide and dimethylfumarate are two new oral therapies for relapsing-remitting multiple sclerosis (RRMS). Due to the increase in patients with these treatments, face-to-face interviews were carried out with these patients in the outpatient area in order to obtain more information....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Hosp Pharm
Main Authors: Torròn, A Martinez, María, MC Rosado, Martínez, A Arias, Fernandez, C Carriles, Romeo, A Llorente, Blanc, R Menarguez, López, E Lázaro, Ferreras, A Rodriguez, López, A Pieras, Tamames, B Zárate, Lozano-Blazquez, A
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Group 2018
Assuntos:
Section 4: Clinical pharmacy services
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535438/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.274
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados